Publications by authors named "Virginia M Kelly"

Claim this Profile
D
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Ian W Flinn, Carole B Miller, Kirit M Ardeshna, Scott Tetreault, Sarit E Assouline, Virginia M Kelly

J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Virginia M Kelly

Blood· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Ian W Flinn, Manish Patel, Yasuhiro Oki, Steven Horwitz, Francine F Foss, Patrick Kelly, Virginia M Kelly

Am J Hematol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Gregory K Friedman, Joshua D Bernstock, Dongquan Chen, Li Nan, Blake P Moore, Virginia M Kelly

Sci Rep· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Ian W Flinn, Susan O'Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Virginia M Kelly, Patrick Kelly

Blood· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.
Eric K Ring, Rong Li, Blake P Moore, Li Nan, Virginia M Kelly

Mol Ther Oncolytics· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Gregory K Friedman, Blake P Moore, Li Nan, Virginia M Kelly, Tina Etminan

Neuro Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.
Gregory K Friedman, Joel Raborn, Virginia M Kelly, Kevin A Cassady, James M Markert

Front Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Joseph G Pressey, Marilyn C Haas, Christine S Pressey, Virginia M Kelly, Jacqueline N Parker

Pediatr Blood Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.
Gregory K Friedman, Marilyn C Haas, Virginia M Kelly, James M Markert, George Yancey Gillespie

Transl Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis